1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Peru Pharmaceuticals and Healthcare Report Q1 2016

Peru Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 86 pages

Includes 3 FREE quarterly updates

BMI View:

Although Peru has still to overcome several institutional shortcomings in public services, its promising economic outlook and its government's commitment to increased investment in the healthcare sector will be factors contributing to the improvement of Peru's pharmaceutical business environment. We believe that, over the next decade, drugmakers and medical device firms will enjoy revenue growth in the country, in the light of efforts to achieve greater health coverage and improved health indicators.


Headline

Expenditure Projections

- Pharmaceuticals: PEN4.67bn (USD1.65bn) in 2014 to PEN4.98bn (USD1.56bn) in 2015; +6.7% in local currency terms and -4.9% in US dollar terms. Forecast unchanged from previous quarter in local currency, downgraded in US dollars due to revised exchange rate expectations.
- Healthcare: PEN31.6bn (USD11.14bn) in 2014 to PEN33.9bn (USD10.65bn) in 2015; +7.2% in local currency terms and -4.5% in US dollar terms. Forecast has been revised downward from Q415 based on
historic data.

Table Of Contents

Peru Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
SWOT 9
Industry Forecast .. 11
Pharmaceutical Market Forecast . 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Peru 2011-2019) 13
Healthcare Market Forecast . 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2011-2019) . . 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2011-2019) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Peru 2011-2019) . . 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Peru 2011-2019) . . 18
Patented Drug Market Forecast .. 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Peru 2011-2019) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Peru 2011-2019) . 23
OTC Medicine Market Forecast .. 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Peru 2011-2019) . 25
Pharmaceutical Trade Forecast .. 26
Table: Pharmaceutical Trade Data And Forecasts (Peru 2013-2019) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Peru 2013-2019) . 28
Industry Risk Reward Indices 29
Americas Risk/Reward Index 29
Peru Risk/Reward Index . 36
Rewards .. 36
Risks . 37
Regulatory Review 39
Intellectual Property Regime .. 41
Pricing Regime .. 43
Table: Peruvian Watchdog of Pharmaceutical Products (Observatorio Peruano de Productos Farmaceuticos, OPPF) . . 44
Reimbursement Regime 44
Table: Price Components Of Two Imported Medicines In Both Private And Public Sectors . 45
Market Overview 46
Market Overview .. 46
Epidemiology . 47
Healthcare Sector . 50
Table: MINSA's Decentralised Institutions and Institutes, 2015 . . 50
Table: Healthcare Resources (Peru 2009-2014) . 52
Table: Healthcare Personnel (Peru 2009-2014) . 53
Table: Healthcare Activity (Peru 2009-2014) . 53
Research and Development . 54
Clinical Trials 55
Competitive Landscape . 57
Research-Based Industry . 57
Table: Multinational Market Activity . 59
Table: Members of ADIFAN, 2014 60
Generic Drugmakers 60
Pharmaceutical Distribution .. 61
Pharmaceutical Retail .. 62
Company Profile . 65
Hersil . 65
Novartis . 68
Sanofi . 70
Unimed .. 73
Demographic Forecast .. 75
Table: Population Headline Indicators (Peru 1990-2025) 76
Table: Key Population Ratios (Peru 1990-2025) . 76
Table: Urban/Rural Population and Life Expectancy (Peru 1990-2025) . . 77
Table: Population By Age Group (Peru 1990-2025) 77
Table: Population By Age Group % (Peru 1990-2025) 78
Glossary .. 80
Methodology . 82
Pharmaceutical Expenditure Forecast Model . 82
Healthcare Expenditure Forecast Model .. 82
Notes On Methodology . 83
Risk/Reward Index Methodology 84
Index Overview .. 85
Table: Pharmaceutical Risk/Reward Index Indicators . 85
Indicator Weightings 86

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.